Literature DB >> 10930974

The story of chronic myeloid leukaemia.

C G Geary1.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10930974     DOI： 10.1046/j.1365-2141.2000.02137.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  18 in total

1.  Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis.

Authors:  Yuka Hirose; Hitoshi Kiyoi; Masanori Iwai; Toshiya Yokozawa; Masafumi Ito; Tomoki Naoe
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

Review 2.  Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.

Authors:  Carsten Denkert; Silvia Darb-Esfahani; Sibylle Loibl; Ioannis Anagnostopoulos; Korinna Jöhrens
Journal:  Semin Immunopathol       Date:  2011-04-17       Impact factor: 9.623

3.  Development of a protease-resistant reporter to quantify BCR-ABL activity in intact cells.

Authors:  Angela Proctor; Imola G Zigoneanu; Qunzhao Wang; Christopher E Sims; David S Lawrence; Nancy L Allbritton
Journal:  Analyst       Date:  2016-10-17       Impact factor: 4.616

Review 4.  Allogeneic stem cell transplantation for chronic myeloid leukemia.

Authors:  Jiří Pavlů; Jane F Apperley
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

Review 5.  Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.

Authors:  Frank S Ong; Kingshuk Das; Jay Wang; Hana Vakil; Jane Z Kuo; Wendell-Lamar B Blackwell; Stephen W Lim; Mark O Goodarzi; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody
Journal:  Expert Rev Mol Diagn       Date:  2012-07       Impact factor: 5.225

Review 6.  Biology-driven cancer drug development: back to the future.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

7.  Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.

Authors:  Hana Salimizand; Sabrieh Amini; Mohammad Abdi; Bayazid Ghaderi; Namam-Ali Azadi
Journal:  Tumour Biol       Date:  2015-08-07

8.  Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia.

Authors:  Kassogue Yaya; Dehbi Hind; Quachouh Meryem; Quessar Asma; Benchekroun Said; Nadifi Sellama
Journal:  Tumour Biol       Date:  2014-08-05

9.  Epidemiological and clinical profile of patients with chronic myeloid leukemia at Health-Care Global, Bangalore Institute of Oncology.

Authors:  K G Srinivas; Shekar Patil
Journal:  Indian J Med Paediatr Oncol       Date:  2013-07

Review 10.  A comprehensive review of protein kinase inhibitors for cancer therapy.

Authors:  Radhamani Kannaiyan; Daruka Mahadevan
Journal:  Expert Rev Anticancer Ther       Date:  2018-10-09       Impact factor: 4.512
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.